ISU Abxis Co., Ltd. (KOSDAQ:086890)
3,850.00
+170.00 (4.62%)
At close: Oct 16, 2026
ISU Abxis Revenue
ISU Abxis had revenue of 14.93B KRW in the quarter ending June 30, 2026, a decrease of -34.61%. This brings the company's revenue in the last twelve months to 51.04B, down -14.10% year-over-year. In the year 2025, ISU Abxis had annual revenue of 56.67B, down -5.95%. That makes ISU Abxis the 29,839th largest company in the world by revenue and 1,855th in South Korea.
Revenue (ttm)
51.04B
Revenue Growth
-14.10%
P/S Ratio
3.08
Revenue / Employee
286.75M
Employees
178
Market Cap
156.98B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | -3.59B | -5.95% |
| Dec 31, 2024 | 60.26B | 5.95B | 10.96% |
| Dec 31, 2023 | 54.31B | 13.14B | 31.91% |
| Dec 31, 2022 | 41.17B | 13.15B | 46.94% |
| Dec 31, 2021 | 28.02B | 2.41B | 9.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| NIBEC | 22.60B |
| Bio Solution | 17.39B |
| TiumBio | 15.00B |
| curacle co.,ltd. | 8.24B |
| IntoCell | 3.19B |
| Y-Biologics | 3.17B |
| Kangstem Biotech | 3.03B |
| Ensol Biosciences | 537.46M |